The US Food and Drug Administration granted Dizal (Jiangsu) Pharmaceutical (SHA:688192) priority review designation for Suvotinib tablets for non-small cell lung cancer, according to a Wednesday filing with the Hong Kong Exchange.
The drug is indicated for locally advanced or metastatic non-small cell lung cancer in patients whose illness has progressed during or after platinum-containing chemotherapy and contains epidermal growth factor receptor exon 20 insertion mutations, the filing said.
The priority review designation is granted to drugs that have attained major safety or efficacy developments for the treatment and diagnosis of certain ailments, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.